Tillkännagivande • Aug 20
Indo Borax & Chemicals Limited (BSE:524342) executed a Share Purchase Agreement to acquire 64.26% stake in Kronox Lab Sciences Limited (NSEI:KRONOX) from Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani and Jogindersingh Gianchand Jaswal for INR 2.5 billion. Indo Borax & Chemicals Limited (BSE:524342) executed a Share Purchase Agreement to acquire 64.26% stake in Kronox Lab Sciences Limited (NSEI:KRONOX) from Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani and Jogindersingh Gianchand Jaswal for INR 2.5 billion on August 20, 2026. Under the terms of the acquisition, Indo Borax & Chemicals Limited will pay INR 103.22 in cash per share or a total of INR 2.46 billion. In a related transaction, Indo Borax & Chemicals Limited proposed to acquire 25.79% stake in Kronox Lab Sciences Limited for INR 1.51 billion. Upon completion of the Transaction, Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani and Jogindersingh Gianchand Jaswal will together hold 9.95% stake in Kronox Lab Sciences Limited. Indo Borax & Chemicals Limited shall appoint 3 nominee directors on the board of directors of the Kronox Lab Sciences Limited and Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani and Jogindersingh Gianchand Jaswal shall resign from the Board.
The completion is subject to fulfilment of closing conditions. The transaction has been approved by the board of directors of Indo Borax & Chemicals Limited. The transaction is expected to close within three months. New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₹6.91b market cap, or US$72.2m). Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹186, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 10% over the past year. Reported Earnings • Aug 14
First quarter 2027 earnings released: EPS: ₹2.00 (vs ₹1.70 in 1Q 2026) First quarter 2027 results: EPS: ₹2.00 (up from ₹1.70 in 1Q 2026). Revenue: ₹296.8m (up 22% from 1Q 2026). Net income: ₹73.0m (up 16% from 1Q 2026). Profit margin: 25% (down from 26% in 1Q 2026). The decrease in margin was driven by higher expenses. Tillkännagivande • Aug 05
Kronox Lab Sciences Limited to Report Q1, 2027 Results on Aug 12, 2026 Kronox Lab Sciences Limited announced that they will report Q1, 2027 results on Aug 12, 2026 Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹158, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 3.5% over the past year. Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹7.51 (vs ₹6.86 in FY 2025) Full year 2026 results: EPS: ₹7.51 (up from ₹6.86 in FY 2025). Revenue: ₹1.06b (up 6.2% from FY 2025). Net income: ₹276.6m (up 8.6% from FY 2025). Profit margin: 26% (in line with FY 2025). Tillkännagivande • May 15
Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026 Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026 Buy Or Sell Opportunity • Apr 06
Now 27% overvalued Over the last 90 days, the stock has fallen 5.5% to ₹131. The fair value is estimated to be ₹103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹119, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year. Buy Or Sell Opportunity • Feb 27
Now 22% overvalued Over the last 90 days, the stock has fallen 16% to ₹120. The fair value is estimated to be ₹98.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses. Tillkännagivande • Feb 09
Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026 Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026 Reported Earnings • Nov 12
Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025) Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025). Tillkännagivande • Nov 04
Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025 Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025 Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Aug 06
Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025 Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025 Upcoming Dividend • Aug 01
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Reported Earnings • Jul 29
Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024) Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue. Tillkännagivande • Jul 28
Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025 Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time. Tillkännagivande • Jul 26
Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025 Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025. Buy Or Sell Opportunity • Jul 07
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%. Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹187, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 24% over the past year. Valuation Update With 7 Day Price Move • May 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India. Reported Earnings • May 23
Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024) Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue. Tillkännagivande • May 19
Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025 Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025 Reported Earnings • Feb 02
Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024) Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue. Tillkännagivande • Jan 23
Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025 Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025 Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India. New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m). Tillkännagivande • Oct 31
Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024 Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India. Tillkännagivande • Aug 09
Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024 Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 India Reported Earnings • Aug 07
First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024) First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Tillkännagivande • Jul 29
Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024 Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024 Tillkännagivande • Jun 22
Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024 Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024 Board Change • Jun 10
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jun 08
Kronox Lab Sciences Limited has completed an IPO in the amount of INR 1.30152 billion. Kronox Lab Sciences Limited has completed an IPO in the amount of INR 1.30152 billion.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 3,349,500
Price\Range: INR 136
Discount Per Security: INR 8.9216
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 1,914,000
Price\Range: INR 136
Discount Per Security: INR 8.9216
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 1,435,500
Price\Range: INR 136
Discount Per Security: INR 8.9216
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 2,871,000
Price\Range: INR 136
Discount Per Security: INR 8.9216
Transaction Features: Regulation S 
